Hsu, Ricky K.
Fusco, Jennifer S. http://orcid.org/0000-0003-1556-811X
Henegar, Cassidy E.
Vannappagari, Vani
Clark, Andrew
Brunet, Laurence
Lackey, Philip C.
Pierone, Gerald Jr.
Fusco, Gregory P.
Funding for this research was provided by:
ViiV Healthcare
Article History
Received: 16 March 2022
Accepted: 27 January 2023
First Online: 13 February 2023
Declarations
:
: OPERA® complies with all HIPAA and HITECH requirements and has received annual institutional review board (IRB) approval by Advarra IRB, including a waiver of informed consent and authorization for use of protected health information (IRB approval #CR00308961). The patients are protected by review by Advarra IRB annually for strictly observational research and on a study-by-study basis for interventional studies.
: Not applicable.
: RKH has received research Grants from Gilead Sciences and Janssen, speaker honoraria and advisory boards from ViiV Healthcare, Merck, Gilead Sciences and Janssen, and advisory board participation with ViiV, Gilead Sciences, Janssen, and Epividian. CEH, VV and AC are employed by ViiV Healthcare and hold stocks and shares in GSK as part of their employment. JSF, LB, and GPF are employed by Epividian, Inc.; Epividian has had research funded by ViiV Healthcare, Merck & Co., Janssen Pharmaceutica, Gilead Sciences, TheraTechnologies, EMD Serono, and AIDS Healthcare Foundation. PCL and GP receive honoraria for advisory board participation with Epividian.